| pubmed-article:20444843 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C1135135 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0210657 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20444843 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:20444843 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:20444843 | pubmed:dateCreated | 2010-10-25 | lld:pubmed |
| pubmed-article:20444843 | pubmed:abstractText | Erlotinib and pemetrexed are approved single agents for second-line treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic antitumor activity in NSCLC cell lines. We investigated the safety, pharmacokinetics and preliminary efficacy of combined erlotinib-pemetrexed in patients with refractory advanced NSCLC. | lld:pubmed |
| pubmed-article:20444843 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20444843 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20444843 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20444843 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:20444843 | pubmed:issn | 1569-8041 | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:TwelvesCC | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:DeanEE | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:RansonMM | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:ReckMM | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:BlatterJJ | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:AnthoneyAA | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:KletzlHH | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:MelezinekII | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:HanauskeA-RAR | lld:pubmed |
| pubmed-article:20444843 | pubmed:author | pubmed-author:Klingelschmit... | lld:pubmed |
| pubmed-article:20444843 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20444843 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:20444843 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20444843 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20444843 | pubmed:pagination | 2233-9 | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:meshHeading | pubmed-meshheading:20444843... | lld:pubmed |
| pubmed-article:20444843 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20444843 | pubmed:articleTitle | Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. | lld:pubmed |
| pubmed-article:20444843 | pubmed:affiliation | Department of Medical Oncology, University of Manchester, Christie Hospital, Manchester, UK. malcolm.ranson@manchester.ac.uk | lld:pubmed |
| pubmed-article:20444843 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20444843 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20444843 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20444843 | lld:pubmed |
